Phase 2 study on a new antiarrhythmic drug in patients with catecholaminergic polymporphic ventricular tachycardia
Catecholaminergic polymorphuic ventricular tachycardia is a rare, inheritable, arrhythmogenic ion channel disease, with patients presenting with syncope at exercise or even sudden cardiac death. Standard of care includes high dosages of beta blockers with the possible addition of calcium channel blockers. The need for an ICD is evaluated individually. Many patients keep having frequent extra systole during exercise, and there are significant side effects to high dosages of beta blockers, hence new nti arrhythmic drugs are of great interest.
The aim of the project is to explore safety, tolerability and efficacy of a new antiarrhythmic drug in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT). The project is in cooperation with with Agiana Pharmaceuticals, a small biotech company developing this new drug from a patent originating from Insititute of basic medical science, University of Oslo. We will include 10 CPVT patients, and monitor them through increasing dosages of the drug, performing exercise stress tests at three different dosages, evaluating safety, tolerability and efficacy.
Researchers involved
- Ida Skrinde Leren, MD/PhD, OUS/UiO
- Kristina Haugaa, MD/Professor, OUS/UiO
Collaborators
- Agiana Pharmaceuticals
- Forskningsenheten OUS Rikshospitalet